CMMB – chemomab therapeutics ltd. - american depositary shares (US:NASDAQ)
Stock Stats
News
Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers
New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab’s Nebokitug in Systemic Sclerosis
Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update [Yahoo! Finance]
Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update
Chemomab Therapeutics Ltd. (NASDAQ: CMMB) had its price target raised by analysts at Maxim Group from $4.00 to $7.00. They now have a "buy" rating on the stock.
Form 20-F Chemomab Therapeutics For: Dec 31
Form 6-K Chemomab Therapeutics For: Mar 27
Form 6-K Chemomab Therapeutics For: Mar 20
Form 6-K Chemomab Therapeutics For: Mar 03
Form 6-K Chemomab Therapeutics For: Feb 19
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.